Immunologiya最新文献

{"title":"Phenotypic and functional features of in vitro generated TCR-T cells specific for the tumor-associated antigen NY-ESO-1","authors":"M. Kuznetsova, V. Tereshchenko, Y. Shevchenko, M. Fisher, V. Kurilin, A. Alsalloum, S. Alrhmoun, Y. Akahori, H. Shiku, S. Sennikov","doi":"10.33029/0206-4952-2022-43-5-536-547","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-5-536-547","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19","authors":"P. A. Talyzin, A. Myasnikov, S. Berns, M. Ilyina, A. Komazov, V. Lynyov, E. V. Ekusheva","doi":"10.33029/0206-4952-2022-43-3-301-311","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-3-301-311","url":null,"abstract":"Background. In vitro studies showed effective viral infection block in case of pretreatment with exogenous interferons. Interferon-gamma is a unique immune interferon, actively expressed in patients with acute respiratory viral infections (ARVI) and defending the body from severe infection course. Aim - to evaluate the safety and preventive effectiveness of nasal interferon-gamma protecting against ARVI, including COVID-19. Material and methods. The study enrolled 630 adult volunteers with a negative PCR test result for SARS-CoV-2, without respiratory symptoms and contraindications to interferongamma. Participants were randomized (1 : 1) into 2 groups: the study group - with the use of a prophylactic course of nasal interferon-gamma, and the group of comparison - without a course of prophylaxis. All participants were given a diary for daily monitor respiratory symptoms, adverse events, and record the use of pharmacotherapy. Results. Safety analysis found no differences between groups. During 28 days period a higher incidence of ARVI, including COVID-19, was observed in the group of comparison (13 vs 3 cases in the study group). The odd ratio was 0.224 (95 % CI: 0.040-0.826), p = 0.020. The total number of ARVI cases, including COVID-19, in the group of comparison during 2 months of research was 26 vs 6 in the study group. The odd ratio was 0.233 (95 % CI: 0.077- 0.594), p = 0,001. The longest period of persistence of respiratory symptoms was obtained in the group of comparison (7 vs 4 days in the study group, p = 0.034). Conclusion. Nasal interferon-gamma as a preventive measure contributes to a decrease of infection incidence of ARVI, including COVID-19.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New approaches to allergen-specific immunotherapy (ASIT): development of a recombinant vaccine against birch pollen allergy","authors":"O. Elisyutina, N. Shershakova, V. Smirnov, I. Shilovskiy, A. Korneev, A. Poroshina, E. V. Smolnikov, A. Litovkina, E.S. Fedenko , D. Kudlay, R. Valenta, M. Khaitov","doi":"10.33029/0206-4952-2022-42-6-621-631","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-42-6-621-631","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection","authors":"I. V. Andreev, K.O. Nechay, A. I. Andreev, A.P. Zubaryova, D. R. Esaulova, A.M. Alenova, I.А. Nikolaeva , O. P. Chernyavskaya, K. S. Lomonosov, A. Shulzhenko, O. Kurbacheva, E. Latysheva, N. Shartanova, E. Nazarova, L. Romanova, N. Cherchenko, V. Smirnov, O. Averkov, А. Martynov, V. Vechorko, G. Gudima, D. Kudlay, R. Khaitov, M. Khaitov","doi":"10.33029/0206-4952-2022-43-1-18-32","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-1-18-32","url":null,"abstract":"Introduction. Mass vaccination of the population against SARS-CoV-2 in Russia and abroad has been going on for more than 2 years. Various types of vaccines are used for vaccination (vector vaccines, RNA vaccines, whole-virion vaccines). The first in the world was registered the Russian vector vaccine «Gam-COVID-Vac» («Sputnik V»), which is widely used in our country, as well as in many other countries of the world. An important area of research is the monitoring of the parameters of the vaccine-induced immune response their analysis in relation to the characteristics of the immune response caused by SARSCoV-2 infection/COVID-19. Such studies are important both for assessing the intensity and duration of post-vaccination immunity, and for improving strategies for immunoprophylaxis and immunotherapy of coronavirus infection. The article presents the results of a study of the humoral immune response in patients with COVID-19 and vaccinated with «Sputnik V» in the period from autumn 2020 till the present time. The aim of the work - a comparative study of the humoral immune response to SARSCoV-2 infection and vaccination against COVID-19. Material and methods. The content of antibodies against SARS-CoV-2 S- and N-proteins was studied in 449 blood serum samples of men and women (age 25-65 years). 5 groups of samples were formed: suffered from COVID-19 of mild and moderate severity, at different times after recovery (262 samples);immunized with the «Sputnik V» vaccine, at different times after injection of the 2nd component of «Sputnik V» (104 samples);suffered from COVID-19 of mild and moderate severity, and then vaccinated with «Sputnik V» (53 samples);vaccinated with «Sputnik V», and then suffered with COVID-19 (12 samples);revaccinated with the vaccine «Sputnik Light» (18 samples). Results. To assess the content of IgG antibodies to S-protein and to N-protein of SARSCoV-2 in human blood sera, an EIA diagnostic system was developed further certified by the Ministry of Health of Russian Federation. In people suffered COVID-19 in 90 % of cases the positive levels of IgG antibodies to SARS-CoV-2 S-protein persist 9 months after recovery, while the proportion of potential plasma donors and material for obtaining intravenous immunoglobulin with a high content of IgG antibodies to S-protein 1 month after the disease is 20 %. In 76 % of people vaccinated with «Sputnik V» high levels of IgG antibodies to S-protein are detected within 6 months after the course of vaccination. The content of IgG antibodies to S-protein in the blood sera of persons suffered COVID-19, and then 6 months after recovery vaccinated with the 1st component of the vaccine «Sputnik V» in 100 % of cases was high with a positivity coefficient above 8.1, regardless of the initial value, already on 7 and 21 days after injection. In persons vaccinated with «Sputnik V» and then passed COVID-19, a high content of S-specific IgG antibodies is observed in 100 % of cases. The examination of vacci","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction of dendritic cells with microorganisms capable of colonizing the intestine","authors":"V. Talayev, I. Zaichenko, M. Svetlova, E. Voronina, O. Babaykina, I. Soloveva, I. Belova, A. G. Tochilina","doi":"10.33029/0206-4952-2022-43-4-412-422","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-4-412-422","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and immunological characteristics of the postcovid period in patients with moderate-severe COVID-19 who received therapy with the inclusion of an IL-6 receptor antagonist","authors":"L. Sizyakina, N. Skripkina, E. Antonova, D. Sizyakin","doi":"10.33029/0206-4952-2022-43-5-606-614","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-5-606-614","url":null,"abstract":"Introduction. Significant progress in clinical research has led to a better understanding of the pathogenesis of COVID-19, contributing to its more effective therapy. The revealed key role of IL-6 in the development and intensification of the <<cytokine storm>>, which has received reliable pathophysiological and pharmacological justification, supports the use of therapeutic strategies aimed at IL-6 or its receptor. Nevertheless, the changes that occur in the immune system after COVID-19 are of interest for a better understanding of the mechanisms of the formation of postcovid syndrome in patients receiving therapy with the inclusion of IL-6 receptor antagonists, its pathogenesis and the search for targets for further therapeutic effects. The aim of the study - to study the clinical and immunological parameters of patients who underwent a moderate-severe variant of COVID-19 and received therapy with the inclusion of IL-6 receptor antagonist during treatment and 6 months after discharge/recovery. Material and methods. 30 hospitalized patients were examined with the diagnosis: COVID-19, moderate-severe form;complication: bilateral polysegmental pneumonia. The comparison group consisted of practically healthy donors (30 people). The dynamics of laboratory parameters (general clinical, biochemical and immunological) were evaluated against the background of therapy with IL-6 blockers at discharge, as well as 6 months after discharge from the hospital, in addition, the quality of life was assessed 6 months after the COVID-19. Results. Postcovid syndrome in patients who have undergone COVID-19 in a moderate-severe form manifests itself in a number of symptoms - decreased appetite, weakness, sleep disorders, depression, headache, shortness of breath, cough, tachycardia, dizziness. In addition, there is an exacerbation of chronic diseases that requires correction in planned therapy. 6 months after discharge from the hospital, there is an increase in CRP and fibrinogen levels, which most likely also reflects the deterioration of the course of concomitant pathology. There is an increase in the level of T-lymphocytes, as well as a decrease in the level of B-lymphocytes. Conclusion. Patients who had COVID-19 require dynamic follow-up. In patients with a moderate-severe form of COVID-19 who received complex therapy with the inclusion of monoclonal antibodies to IL-6 receptors, dexamethasone, antiviral therapy, anticoagulants, oxygen therapy, there are dysregulatory processes in the immune system that persist 6 months after recovery. Copyright © 2022 Meditsina Publishers. All rights reserved.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The content of platelet-leukocyte coaggregates in the peripheral blood of healthy children of different ages","authors":"Ye.N. Bogomyagkova, A. Solpov, P. Tereshkov, N.G. Trushina, Y. Vitkovskiy","doi":"10.33029/0206-4952-2022-43-6-702-713","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-6-702-713","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mast cell involvement in physiological and preeclampsia complicated pregnancy","authors":"I. M. Bogdanova, K. Artemieva, M. N. Boltovskaya, M. Kondashevskaya, N. V. Nizyaeva","doi":"10.33029/0206-4952-2022-43-6-736-745","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-6-736-745","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of interaction between circulating CD4+CCR6+ T cells and B-lymphocytes","authors":"V. Talayev, E. Voronina, M. Svetlova, I. Zaichenko, O. Babaykina","doi":"10.33029/0206-4952-2022-43-3-266-276","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-3-266-276","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of respiratory hypoxic gas mixtures (oxygen-nitrogen and oxygen-nitrogen-argon) in a pressure chamber on the state of the human cellular immunity","authors":"E. A. Lysenko, V. A. Shmarov, M. Rykova, E. Antropova, O. Kutko, S. Shulgina, K. Orlova, E.A. Zhirova, A. Sadova, D. D. Vlasova, S. Ponomarev","doi":"10.33029/0206-4952-2022-42-6-643-653","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-42-6-643-653","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}